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Abstract Cellular senescence is a highly complex and programmed cellular state with diverse 
and, at times, conflicting physiological and pathological roles across the lifespan of an organism. 
Initially considered a cell culture artifact, senescence evolved from an age- related circumstance to an 
intricate cellular defense mechanism in response to stress, implicated in a wide spectrum of biolog-
ical processes like tissue remodelling, injury and cancer. The development of new tools to study 
senescence in vivo paved the way to uncover its functional roles in various frameworks, which are 
sometimes hard to reconcile. Here, we review the functional impact of senescent cells on different 
organismal contexts. We provide updated insights on the role of senescent cells in tissue repair and 
regeneration, in which they essentially modulate the levels of fibrosis and inflammation, discussing 
how “time” seems to be the key maestro of their effects. Finally, we overview the current clinical 
research landscape to target senescent cells and contemplate its repercussions on this fast- evolving 
field.
Cellular senescence: a story between life and death
Cellular senescence was formerly described by Hayflick and colleagues, after witnessing that normal 
diploid cells in culture had a limited number of cell divisions and entered a permanent cell cycle arrest 
(Hayflick and Moorhead, 1961). Hayflick observed that the nondividing cells remained viable for 
many weeks and suggested that this proliferative halt and finite lifetime in vitro represented aging 
at the cellular level (Hayflick, 1965). Several decades later, Hayflick’s proposal was corroborated by 
attributing this proliferation limit to a progressive telomere shortening after propagation of cells in 
culture, which is now known as replicative senescence (Harley et al., 1990). The link between replica-
tive senescence and aging was further reinforced when an age- dependent accumulation of cells exhib-
iting senescence markers in vivo was revealed (Dimri et al., 1995). Two years later, a landmark study 
demonstrated that the expression of active mitogenic oncogenes (such as Ras) induced senescence in 
primary cells regardless of the age (Serrano et al., 1997). This process was coined oncogene- induced 
senescence (OIS) and introduced the concept of senescence working as a tumour- suppressive mecha-
nism to prevent aberrant proliferation after an oncogenic stimulus. Since then, it has been established 
that cellular senescence can be induced by a wide range of different stress signals, such as oxidative 
stress (Chen et al., 1995), chemotherapy (Schmitt et al., 2002), induced- pluripotent stem (iPS) cell 
reprogramming (Krizhanovsky and Lowe, 2009), irradiation (Le et al., 2010), or cytokine treatment 
(Braumüller et al., 2013). It became then clear that senescence and aging are not synonymous and 
that senescent cells (SCs) can be triggered by several stressful insults independently of organismal age 
(Rodier and Campisi, 2011; Figure 1).
Importantly, SCs stopped being regarded as just undead or zombie cells that refuse to die. Though 
one might say they walk a fine line between life and death, it is now clear that SCs are much more than 
what was initially thought. In fact, they suffer numerous phenotypic changes and remain metabolically 
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active cells with a complex secretory phenotype, through which they can modify the surrounding micro-
environment (Muñoz- Espín and Serrano, 2014; Figure 1). Strikingly, SCs have recently emerged as 
beneficial players in various physiological processes, from embryonic development to cellular repro-
gramming and tissue injury responses such as wound healing and tissue repair (Rhinn et al., 2019).
What truly defines a SC?
Cellular senescence has several biomarkers but none is absolutely specific (Figure 1). The cell cycle 
arrest is not exclusive of senescence and pRB and p53 are also involved in other forms of proliferative 
withdrawal (Rodier and Campisi, 2011). Even p16INK4a, one of the strongest senescence markers, 
might not be expressed in all SCs and is expressed in certain non- SCs (Hernandez- Segura et al., 
Figure 1. The hallmark features of cellular senescence. Cells may be induced to senesce by different stimuli, including telomere erosion, oncogene 
activation (oncogene- induced senescence [OIS]), DNA damage, oxidative stress, irradiation, chemotherapy, induced pluripotent stem cell (iPSC) 
reprogramming, developmental cues, and tissue damage. These stresses trigger the upregulation of key cell cycle inhibitors, namely p16INK4a, p21CIP1, 
p53, p15INK4b, p14ARF, and p27KIP1, leading to a permanent cell cycle arrest (either in G1 or G2 phase). BCL- 2 and PI3K/AKT anti- apoptotic pathways 
also become upregulated, bestowing senescent cells (SCs) with resistance to apoptotic cues. Other phenotypic alterations include an enlarged cell 
size (up to 2.5 times the normal counterpart) and metabolic changes such as mitochondrial and lysosomal expansion, which increase the production 
of reactive oxygen species (ROS) as well as the activity of lysosomal senescence- associated β-galactosidase (SA-β-gal, detected at pH 6.0). ROS 
accumulation induces protein aggregates which crosslink with sugars and lipids and form insoluble lipofuscin aggresomes. Autophagy rate is increased 
during the early senescence programme but is highly compromised in later stages. SCs are characterized by a complex senescence- associated 
secretory phenotype (SASP) that comprises a plethora of different growth factors, cytokines, chemokines, proteases, and matrix components. Primary 
transcriptional activators of the SASP include nuclear factor kappa B (NF-κB), CCAAT/enhancer binding protein β (c/EBPβ), and mammalian target 
of rapamycin (mTOR). SASP factors, such as IL- 6, IL- 8, Gro-α, IGFBP- 7, and PAI- 1, reinforce the senescence programme in an autocrine manner, 
while others, like ROS, IFN-γ, TGF-β, IL- 1α, VEGF, CCL2, and CCL20, induce paracrine senescence in neighbouring cells. Upon the initiation of the 
senescence programme, the chromatin suffers deep modifications towards the repression of proliferation- related genes and the stimulation of SASP- 
related genes. This results in the appearance of DNA segments with chromatin alterations reinforcing senescence (DNA- SCARS) as well as senescence- 
associated heterochromatic foci (SAHF). Chromatin alterations are accompanied by a downregulation of lamin B1, a major component of the nuclear 
lamina, compromising its integrity and leading to the extravasation of chromatin fragments into the cytosol. Cytosolic chromatin fragments (CCFs) 
are recognized by cyclic GMP- AMP synthase (cGAS) which, in turn, triggers the activation of stimulator of interferon genes (STING). The cGAS- STING 
pathway stimulates pro- inflammatory SASP responses through upregulation of NF-κB. Recent studies suggest that urokinase- type plasminogen 
activator receptor (uPAR), a cell- surface protein, is also broadly expressed during senescence. The biomarkers in bold represent the most common 
hallmark features of cellular senescence. None of these hallmarks is exclusively specific and their manifestation can diverge according to the nature of 
the senescence trigger, the cell/tissue type and time of the senescence programme.
 Review article Cell Biology
Paramos- de- Carvalho et al. eLife 2021;10:e72449. DOI: https:// doi. org/ 10. 7554/ eLife. 72449  3 of 21
2017; Sharpless and Sherr, 2015). The p53/p21CIP1 pathway does not always drive senescence and, 
in some tissues, cells that stain positively for senescence- associated β-galactosidase (SA-β-gal) lack 
the expression of p21CIP1 (Huang and Rivera- Pérez, 2014; Xu et al., 2019). In fact, despite its prom-
inence, SA-β-gal is not a requirement of the senescent phenotype and it is possible to have SA-β-gal- 
negative SCs (e.g., those lacking GLB1) (Lee et al., 2006). In addition, false- positive SA-β-gal staining 
was also detected in macrophages (Hall et  al., 2017). DNA segments with chromatin alterations 
reinforcing senescence (DNA- SCARS) and senescence- associated heterochromatic foci (SAHF) are 
stimulus- dependent and therefore cannot be regarded as a global feature of SCs (Di Micco et al., 
2011; Kennedy et al., 2010; Rodier et al., 2011). The senescence- associated lipid profile seems 
to be variable depending on the trigger and mitochondrial dysfunction also portrays other cellular 
processes, so none of these are absolute biomarkers of senescence (Eisner et al., 2018; Quijano 
et al., 2012).
Even though senescence is traditionally associated with a transition into a proliferative arrest, it has 
become clear that terminally differentiated cells can develop a senescent phenotype. For instance, 
post- mitotic neurons in the cortex in both rodent and human aging brains were shown to exhibit 
several senescence features (Chinta et al., 2015; Jurk et al., 2012; Kang et al., 2015; Moreno- Blas 
et al., 2019; Walton and Andersen, 2019) and more recently, senescent neurons were also shown to 
be induced after spinal cord injury (Paramos- de- Carvalho et al., 2021).
Among the hallmarks of senescence, perhaps the most relevant one is the development of a 
complex secretory programme denominated as senescence- associated secretory phenotype (SASP), 
which was originally described by the Campisi group (Krtolica et al., 2001). Through the SASP, which 
comprises a plethora of different growth factors, chemokines, cytokines, extracellular matrix (ECM) 
components and proteases (Figure 1), SCs modulate the surrounding environment, exerting their 
pathophysiological effects (Le et al., 2010). Thus, cellular senescence has been implicated in a wide 
range of distinct biological activities, from aging and tumour progression or suppression to develop-
ment, wound healing, and even regeneration (Rhinn et al., 2019; Rodier and Campisi, 2011).
The concept of paracrine senescence (senescence- induced senescence) is essential to understand 
the impact of the propagation of a senescence response in the tissue microenvironment. Continuous 
exposure to the SASP induces senescence in bystander normal cells, both in vitro and in vivo (Acosta 
et al., 2013; Nelson et al., 2012). Therefore, paracrine senescence has been shown to mediate the 
deleterious effects of SCs on tissue homeostasis, namely in promoting tumourigenesis and aging- 
related organ dysfunction, as well as in impairing regeneration (Campisi, 2005; Ferreira- Gonzalez 
et al., 2018; Gonzalez- Meljem et al., 2018).
Given the nature of the SASP, senescence signalling is often linked to inflammation. Remarkably, 
some SASP factors, such as colony stimulating factor 1 (CSF1), CCL2, and IL- 8 recruit the immune 
system to promote self- clearance of SCs (Muñoz- Espín and Serrano, 2014). This seems to be critical 
to control the levels of SCs in a given setting and prevent chronic inflammatory responses.
It is clear that the manifestation of each senescence hallmark is context- dependent and varies 
according to factors such as the stress trigger, the cell or tissue type, and, last but not least, time from 
induction of the senescence programme (Calcinotto et al., 2019). Besides this huge heterogeneity, 
one must also account for the fact that non- SCs (even proliferative cells) may express some of the 
features normally associated with senescence. An example is the difficulty in often distinguishing 
whether secreted factors have a SASP origin or are molecules secreted by other non- SCs. This is why a 
multi- parametric approach is required in order to define a senescence signature. Data from transcrip-
tome analysis and single- cell studies is proving to be a valuable tool in providing senescence- gene- 
expression signatures in several different conditions. For example, a proteomic atlas of SASP factors 
originating from senescent fibroblasts and epithelial cells submitted to multiple senescence inducers 
has been recently reported (Basisty et al., 2020). This type of comprehensive analysis is fundamental 
to define biomarker candidates with greater selectivity to specific pathological contexts, but infor-
mation is still lacking and more studies are needed, especially in vivo. Meanwhile, a three- step multi- 
marker system has been proposed to identify SCs with more accuracy. This multi- marker workflow 
includes: (1) screening for senescence with SA-β-gal and/or lipofuscin accumulation; (2) co- staining 
with markers frequently present (p16INK4a, p21CIP1) or absent (proliferation markers, Lamin B1) in SCs; 
and (3) identification of factors predicted to be altered in specific senescence contexts (SASP, DNA 
damage, PI3K/FOXO/mTOR) (Gorgoulis et al., 2019).
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Senescence: the good, the bad, and the ugly
The discovery of additional cellular senescence features and biological roles provided a shifting view 
from a simple cell autonomous stress response to a dynamically active mobilization of environmental 
signalling cues with local or systemic repercussions for tissue function and, ultimately, organismal life. 
Some of these repercussions are beneficial while others are detrimental (Figure 2). In some contexts, 
these seemingly paradoxical roles are challenging to reconcile, justifying the apparent chaotic nature 
of this yet undeciphered phenomenon.
Aging
In zebrafish, rodents, primates, and humans, SCs are found in many tissues throughout life (Campisi, 
2005; Dimri et al., 1995; Jeyapalan et al., 2007; Kishi, 2004). Though relatively rare in young organ-
isms, they accumulate with age in several organs and tissues, such as the skin, heart, lung, spleen, 
kidney, and liver (Wang et al., 2009; Yang and Fogo, 2010). Aging entails a progressive loss of tissue 
functions that eventually leads to several chronic and age- related diseases (Campisi, 2013). So, a 
causal link between cellular senescence and aging seems quite plausible. In fact, senescence has been 
associated to a wide range of human age- associated pathologies, including cancer, fibrosis, cardio-
vascular diseases, type 2 diabetes, obesity, sarcopenia, osteoarthritis, osteoporosis, and neurological 
Figure 2. A time- gated model for the senescence- associated secretory phenotype (SASP)- mediated biological activities of cellular senescence. The 
SASP can have a wide range of effects in the surrounding microenvironment, including matrix remodelling, mitogenic signalling, clearance regulation, 
inflammation, immune modulation, cell proliferation, migration, differentiation and plasticity, as well as vascularization. Depending on the time 
duration of the senescence programme and the associated SASP response, effects can be beneficial or detrimental. Anti- fibrotic and anti- inflammatory 
effects are normally correlated to a transient SASP and favour tissue repair and regeneration. A short- term SASP also favours immune- mediated 
clearance of SCs in order to avoid their accumulation and persistence. Likewise, a transient senescence profile is fundamental for tissue patterning 
during development. In contrast, long- lasting SASP responses have detrimental pro- fibrotic and pro- inflammatory effects on the microenvironment. 
Therefore, the persistent accumulation of SCs leads to tissue dysfunction and is associated with chronic inflammation and a broad spectrum of aging- 
related diseases. Persistent senescence responses can also deplete stem cell progenitor pools, impairing the repair/regenerative capability of affected 
tissues. In turn, the role of the SASP in cancer is more ambiguous than the rest, as SCs can both promote tumour suppression and tumour progression/
invasiveness. However, current knowledge suggests that the SASP suppresses tumour growth in early stages, while supplying pro- tumourigenic chronic 
inflammatory environments in later stages.
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disorders (Calcinotto et al., 2019; van Deursen, 2014). Remarkably, the use of progeroid mouse 
models has provided evidence that ablation of p16INK4a+ cells improves many of these disease symp-
toms, reinforcing a detrimental role of SCs in aged tissues (Baker et al., 2011; Rhinn et al., 2019).
Some studies have also suggested that, with aging, senescence plays a role in the decline of regen-
erative capacity, namely by functionally depleting stem cell progenitor pools (Braun et  al., 2012; 
Janzen et al., 2006). This was recently proposed during skeletal muscle regeneration in aged mice 
(Sousa- Victor et al., 2014). Through aging, geriatric muscle stem cells (MuSCs) suffer a quiescence- 
senescence switch triggered by an age- associated increase in p38MAPK activation and p16INK4a 
expression, becoming unable to activate and expand upon injury. Importantly, inhibition of p38MAPK 
or p16INK4a restored quiescence and regenerative functions in MuSCs (Cosgrove et al., 2014; Sousa- 
Victor et al., 2014). In the aging heart, cardiac progenitor cells (CPCs) progressively lose their regen-
erative capacity, as senescent CPCs render other healthy CPCs to senesce (Lewis- McDougall et al., 
2019). It is still unclear if differentiated muscle cells develop senescent phenotypes, as they age, and 
consequently induce senescence in stem cell progenitor pools in a paracrine manner.
Similar to a ‘chicken or the egg’ paradox, one might wonder whether it is the accumulation of 
SCs that leads to aging or the opposite. The mechanisms behind SC accumulation with age and their 
influence on disease progression are still unclear. Some hypothesize that SCs develop ways to escape 
from immunosurveillance. In support of this, authors have shown that senescent dermal fibroblasts 
express atypical levels of MHC molecule HLA- E, induced by SASP- associated cytokines and regulated 
by p38MAPK (Pereira et al., 2019). HLA- E interacts with the inhibitory receptor NKG2A expressed 
by natural killer (NK) and highly differentiated CD8+ T cells, allowing senescent fibroblasts to evade 
immune clearance. Others theorize that, with age, the immune system becomes progressively compro-
mised (immunosenescence) and cannot efficiently clear SCs as it should or that the generation rate of 
SCs is just too big to cope with (Furman et al., 2019). In any case, there is a very important notion to 
take from the relationship between senescence and aging: a persistent accumulation of SCs without 
a controlled clearance is detrimental for tissue function.
Cancer
Cellular senescence is a powerful barrier to tumourigenesis (Collado and Serrano, 2010). The first 
experimental evidence of OIS came from the overexpression of oncogenic Ras in human fibroblasts, 
resulting in upregulation of p53, p16INK4a, pRB, and permanent cell cycle arrest (Serrano et al., 1997). 
This can be bypassed by inactivation of p53 and p16INK4a or co- expression of other oncogenes like 
c- MYC, E1A, or DRIL1 (Serrano et  al., 1997). BRAF is another oncogene that promotes OIS by 
inducing p16INK4a expression, in a process that requires the co- expression of IGFBP7 (Wajapeyee 
et  al., 2008). The loss or inactivation of tumour suppressor genes, such as PTEN, also induces a 
senescence response (Chen et al., 2005). Loss of PTEN induces p53 through activation of mTOR and 
ARF- mediated inhibition of MDM2, but also p16INK4a through upregulation of the transcription factor 
Ets2 (Ohtani et al., 2001). Contrarily to OIS, PTEN loss- induced senescence occurs in the absence 
of DNA damage response (DDR) but can also be bypassed by p53 inactivation (Ohtani et al., 2001).
The SASP of senescent tumour cells modulates the tumour microenvironment, which is also 
composed of non- senescent proliferating tumour cells, stromal cells, and infiltrating immune cells 
(Calcinotto et al., 2019). Thus, the SASP can act as another blocker of tumour growth by reinforcing 
autocrine senescence or inducing paracrine senescence in neighbouring tumour cells. For example, 
release of IL- 1α by SCs spreads senescence to normal and tumour cells (Di Mitri and Alimonti, 2016). 
On the other hand, inhibition of IL- 1α and IL- 6 promotes OIS evasion (Di Mitri and Alimonti, 2016; 
Kuilman et al., 2008). Importantly, some SASP factors of tumour cells, such as TGF-β, VEGF, CCL2, 
and CCL20, also induce senescence in normal cells (Acosta et al., 2013). Highly relevant for tumour 
regression is the efficient removal of senescent tumour cells by immune cells that are recruited by 
the SASP itself (Vicente et al., 2016). Likewise, the immune response can then limit tumourigenesis 
by releasing factors, such as IFN-γ, TNF-α (tumour necrosis factor alpha), and TGF-β, in the tumour 
microenvironment and inducing senescence in tumour cells, generating a positive feedback loop 
(Braumüller et al., 2013; Calcinotto et al., 2019; Reimann et al., 2010). Yet, the SASP can also have 
immunosuppressive properties, attracting a high number of infiltrating myeloid- derived suppressor 
cells (MDSCs) that block the effect of other immune effector populations and inhibit the senescence 
response by releasing IL- 1 receptor antagonist in the tumour microenvironment (Di Mitri et al., 2014).
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Strikingly, the SASP of senescent tumour cells can also promote tumour progression, driving tumour 
vascularization and invasiveness through secretion of VEGF and a number of different matrix metal-
loproteinases (MMPs) (Coppé et al., 2006; Coppé et al., 2010). Several other SASP factors, such as 
Gro-α, basic fibroblast growth factor, and PAI- 1, have been shown to stimulate malignant cell growth 
and cancer invasion. Secretion of IL- 6 and IL- 8 has been shown to promote both tumourigenesis and 
tumour suppression in different contexts (Rodier and Campisi, 2011). The SASP stands, therefore, as 
a double- edged sword, eliciting both antitumourigenic and tumour- promoting effects. SASP effects 
on cancer progression/suppression seem to rely not only on the context but also on the persistence 
of SCs through time. In line with this, a recent study has shown that telomerase- deficient zebrafish, 
who exhibit an accumulation of senescence similar to human aging, display increased systemic chronic 
inflammation through time, which potentiates cancer incidence and invasiveness (Lex et al., 2020). In 
fact, pre- cancer lesions developed into cancer at twice the rate if neighbouring tissues were senescent.
Chemotherapy drugs or ionizing radiation are used to induce senescence in cancer cells, in what 
is called therapy- induced senescence (TIS) (Calcinotto et al., 2019). The mechanisms underlying TIS 
are usually connected to the DDR. Presently, several TIS drugs are used for human cancer treatment, 
including Palbociclib, Doxorubicin, Bleomycin, Docetaxel, Cyclophosphamide, Etoposide, Vincristine, 
and Cisplatin (Ewald et al., 2010). Among all of them, the CDK4/6 inhibitor Palbociclib is currently 
considered the most relevant prosenescent compound in the clinic. However, in spite of its efficiency 
in blocking tumour cell proliferation, TIS must be used and monitored with attentive care. By also 
affecting normal cells, the senescence response might be so intense that the immune system fails 
to efficiently clear SCs from the tumour microenvironment. Indeed, the accumulation of SCs after 
TIS has been shown to promote tumour relapse with increased malignancy and premature aging 
features in human adults and children after chemotherapy (Marcoux et al., 2013; Ness et al., 2015). 
Furthermore, a recent study has demonstrated that, after TIS, some senescent tumour cells are able 
to escape from cell cycle blockade and acquire stemness properties with highly aggressive growth 
potential, which contradicts the terminal proliferative phenotype and has profound implications for 
the treatment outcome (Milanovic et al., 2018). This has been suggested as a form of tumour cell 
evasion from therapy, allowing their survival in a transient dormant state with potential to recover self- 
renewal capacity and lead to disease recurrence, normally with increased malignancy (Saleh et al., 
2019). This led to a reassessment of treatment strategies, in view of taking advantage of the benefi-
cial effects of senescence in blocking cancer cell proliferation but controlling subsequent detrimental 
outcomes due to its accumulation. As a result, current therapeutic strategies generally encompass a 
double approach, involving an initial pro- senescent step followed by an anti- senescent phase (Calci-
notto et al., 2019). In summary, chemo/radiotherapy or senescence- inducing drugs can be combined 
with senolytic drugs that eliminate excess senescent tumour cells that are not efficiently cleared by 
the immune system. Additionally, modulation of the SASP or MDSC function (e.g. with antagonists of 
CXCR2, a receptor for several SASP cytokines) may be used to enhance the efficacy of pro- senescence 
therapies and promote senescence immune surveillance (Calcinotto et al., 2019; Toso et al., 2014).
The role of senescence in cancer rightfully epitomizes the good, the bad, and the ugly sides of this 
cellular phenomenon, by suppressing tumour growth in early stages, contributing to tumour devel-
opment in later stage and eliciting tumour relapse and increased malignancy after arrest escape or 
chemotherapy. Importantly, with aging, this scenario becomes even more grim as SCs accumulate and 
supply pro- tumourigenic chronic inflammatory environments.
Development
The discovery of SCs throughout embryonic development was very exciting and brought relevant 
insights to better understand the physiological roles of senescence. So far, SCs have been found 
during development of mouse and human embryos (Chuprin et al., 2013; Muñoz- Espín et al., 2013; 
Storer et al., 2013), but also in naked mole rats (Zhao et al., 2018), birds (Gibaja et al., 2019; Nacher 
et al., 2006; Storer et al., 2013), amphibians (Davaapil et al., 2017; Villiard et al., 2017), and fish 
(Da Silva-Álvarez et al., 2020; Villiard et al., 2017) embryos and/or larvae. SCs in developing embry-
onic structures exhibit SA-β-gal activity and upregulation of p21CIP1, while expression of other senes-
cence markers, like p53, p16INK4a, and DDR, is absent (Muñoz- Espín et al., 2013). This suggests a 
different senescence phenotype from that observed later in life and pinpoints the relevance of p21CIP1 
in developmental senescence. Indeed, genetic disruption of p21CIP1 or senolytic treatment results in 
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loss of senescence and patterning abnormalities in various structures (Davaapil et al., 2017; Gibaja 
et al., 2019; Muñoz- Espín et al., 2013; Storer et al., 2013). Interestingly, patterning defects are 
only observed transiently and are eventually compensated by other mechanisms, namely apoptosis 
(Muñoz- Espín et al., 2013; Storer et al., 2013). This suggests that SCs are intrinsic to development 
but not essential.
Overall, existing studies suggest that developmental senescence is not a damage- triggered event 
but rather a highly organized and programmed process with precise patterns in time and space, which 
may be orchestrated by other cues such as biophysical forces during morphogenesis. During devel-
opment, SCs seem to contribute to tissue remodelling by controlling the balance of cell populations, 
fine- tuning of cell fate specification, morphogenetic signalling, and structural degeneration (the latter 
mediated by macrophage- dependent elimination).
Wound healing and tissue repair
A role of senescence in wound healing and tissue repair has been described in several organs, such as 
the liver (Krizhanovsky et al., 2008), the skin (Demaria et al., 2014; Jun and Lau, 2010), the heart 
(Meyer et al., 2016; Zhu et al., 2013), and the lung (Schafer et al., 2017; Table 1). In all cases, SCs 
seem to be closely associated with the levels of fibrotic tissue generated upon wound resolution, which 
in turn affect the outcome of the repair process (Baker et al., 2016; Yun, 2018). The deposition of 
ECM is critical for the maintenance of tissue integrity during wound healing but, if left unchecked, may 
lead to fibrosis and scarring. In the skin, CCN1, a matricellular protein expressed upon wound healing, 
elicits a senescence response in fibroblasts by triggering p53 and p16INK4a via ERK and p38MAPK path-
ways (Jun and Lau, 2010). This response controls the proliferation of fibroblasts and ECM deposition, 
limiting the fibrotic scar and contributing to the healing process. Importantly, defects in CCN1 lead to 
fibrosis exacerbation (Jun and Lau, 2010). Also in the skin, in a more recent study using the p16- 3MR 
transgenic model, Demaria and colleagues demonstrated that a transient accumulation of senescent 
fibroblasts and endothelial cells at the wound site induces myofibroblast differentiation through secre-
tion of platelet growth factor AA (PDGF- AA) (Demaria et al., 2014). Elimination of p16+ cells resulted 
in delayed wound healing and increased fibrosis. Notably, topical administration of PDGF- AA reverted 
the delay in wound closure while maintaining the levels of fibrotic tissue, suggesting more SASP 
factors (likely MMPs) are involved in the healing process. In a mouse model of chronic liver damage, 
the administration of CCl4 induces fibrotic scarring and senescence in hepatic stellate cells (HSCs) 
also via a CCN1/p53/p16INK4a pathway (Krizhanovsky et al., 2008). Senescent HSCs facilitate fibrotic 
resolution through secretion of MMPs. Finally, the cycle is completed by recruitment of NK cells to 
promote their own elimination. Moreover, p53;INK4A/ARF null mice displayed decreased numbers 
of senescent HSCs and extensive cirrhosis upon CCl4 treatment (Krizhanovsky et al., 2008). A time- 
controlled SASP- mediated clearance of SCs seems to be, in fact, a fundamental step for the outcome 
of the repair process. In a recent study using both human and mouse models of ischemic retinopathy, 
the SASP of senescent endothelial cells stimulated neutrophil recruitment and the extrusion of neutro-
phil extracellular traps, which both removed dysfunctional endothelial SCs and facilitated vascular 
pruning and repair (Binet et al., 2020).
The contrasting effects of transient vs. persistent senescence responses are further substantiated 
upon cardiac injury. In mouse models of cardiac hypertrophy and heart infarction, cardiac myofibro-
blasts enter senescence through a CCN1- dependent manner, reducing fibrosis in the short- term and 
improving heart function (Meyer et al., 2016; Zhu et al., 2013). However, after cardiac ischaemia- 
reperfusion injury, a long- term oxidative stress- induced senescence response in cardiomyocytes and 
interstitial cells promotes fibrosis and mediates a pro- inflammatory SASP, impairing heart function 
(Dookun et al., 2020). Similarly, in a mouse model of idiopathic pulmonary fibrosis (IPF), a chronic 
lung disease characterized by decreased lung function due to persistent scarring, senescent epithelial 
cells and fibroblasts accumulate continuously over time, inducing myofibroblast differentiation and 
exacerbating the fibrotic response (Schafer et al., 2017). In this case, the elimination of SCs improves 
the disease condition.
Together, these results suggest that timely and coordinated activation of SCs controls the early 
fibrotic response and is beneficial for wound repair. Yet, in the absence of proper clearance, persistent 
SCs accumulate and have a negative impact in tissue repair (Figure 2).
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Regeneration
Though still a very understudied topic, recent findings suggest that SCs have indeed a part to play 
in regenerative processes (Table 1). In 2015, the team of Jeremy Brockes (UCL, London) reported 
a recurrent turnover of senescence during limb regeneration in the salamander (Yun et al., 2015). 
SCs were transiently induced near the amputation plane throughout regeneration and subsequently 
cleared by a macrophage- dependent immunosurveillance mechanism. This finding led to the obvious 
question of whether these transient SCs could be contributing to the regenerative response. Consid-
ering that salamanders regenerate limbs through dedifferentiation (Tanaka et al., 2016), this model 
constitutes a good system to study the impact of senescence on this particular process of cellular 
plasticity. However, due to the scarcity of tools to manipulate SCs in this model and assess their func-
tion, it is still unclear how senescence contributes to limb regeneration. One hypothesis is that SCs 
might stimulate dedifferentiation and/or create a more pro- regenerative microenvironment through 
the SASP (e.g., ECM remodelling, vascularization). Recruited immune cells, namely macrophages and 
NK cells, can also execute pro- regenerative functions (Godwin et al., 2013; Lucas et al., 2010; Raja-
gopalan and Long, 2012). Another possibility is that SCs work as a population balancing mechanism, 
controlling the proliferation of certain cell types during tissue re- growth and patterning, much like 
during development. Yet, it is possible that SCs are just a consequence of the local tissue damage 
cues from the injury and need to be removed, which then still raises the question of why not follow the 
apoptosis route instead. Whatever the case, current understanding of the functions of cell senescence 
tells us that these cells are likely modulating the surrounding microenvironment.
So far, very few studies have associated cellular senescence to regeneration, with most being 
accounted for during the past 5 years. In 2019, a transient burst of SA-β-gal+ cardiac fibroblasts was 
reported in zebrafish and neonatal mouse hearts after an injury (Sarig et al., 2019). Even though the 
effects of senescence on cardiac regeneration are yet to be determined, a study from 2015 demon-
strated that telomerase- deficient zebrafish display an aberrant accumulation of SCs and fail to regen-
erate their hearts (Bednarek et al., 2015). Also in 2019, another study showed evidence of a transient 
accumulation of SCs after zebrafish caudal fin amputation (Da Silva‐Álvarez et al., 2019). In this case, 
tissue regeneration was impaired by removal of SCs with a senolytic drug, a type of drug that acts by 
inducing apoptosis in SCs (Zhu et al., 2015).
Yet, the association of senescence with regeneration phenomena goes beyond organisms with 
outstanding regenerative capabilities. In a mouse model of chronic inflammatory myopathy, senes-
cence of fibro- adipogenic progenitors (FAPs) in response to exercise- induced muscle damage is 
necessary to promote functional recovery and muscle regeneration (Saito et al., 2020). In addition, 
the expression of p53 was found to be upregulated in the rat soleus muscle after a spinal cord injury 
(Graham et al., 2020). This upregulation disappears 3 months after injury, accompanied by a reduc-
tion in the expression of p16INK4a. Even though this study lacks the identification of some key senes-
cence biomarkers, such as SA-β-gal and p21CIP1, it does seem to point to another transient turnover of 
SCs in tissues with regenerative capacity.
In a mouse model of biliary injury, TGF-β secretion- mediated paracrine senescence of cholangio-
cytes and hepatocytes was shown to have deleterious repercussions in the surrounding microenviron-
ment and impair liver regeneration (Ferreira- Gonzalez et al., 2018). The inhibition of TGF-β signalling 
disrupted the continuous propagation of senescence, reduced collagen deposition, and restored liver 
function. This work attests the detrimental impact of a persistent SASP exposure in regenerative 
paradigms.
In our lab, we have recently provided evidence that there are distinct senescence responses 
induced after a spinal cord injury between two animal models with different regenerative capabilities 
(Paramos- de- Carvalho et  al., 2021). In this study, the regenerating zebrafish exhibits a transient 
accumulation of SCs at the lesion periphery, which are then cleared out. In contrast, in the injured 
mice SCs persistently accumulate over time and are not eliminated. Targeting of SCs in the mouse 
spinal cord in order to prevent their accumulation after injury resulted in improved motor, sensory, 
and bladder functions, supported by beneficial effects on myelin preservation, axonal growth, fibrotic 
resolution, and inflammation. These effects were accompanied by a reduced secretion of pro- fibrotic 
and pro- inflammatory factors in the injury microenvironment (Table 1). This work highlights the role of 
SCs in modulating the spinal cord injury microenvironment, which is permissive for regeneration in the 
zebrafish but is inhibitory in mammals.
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Transversal to all these reports is the timely elimination of SCs, which suggests that their persistence 
could eventually turn detrimental for the regenerative response. Current knowledge seems to support 
this hypothesis, given the outcome of transient vs. persistent SASP exposure in pathological condi-
tions or aging.
Reprogramming
Recent studies have uncovered another unexpected facet of senescence: a role in cellular repro-
gramming. This facet became even more interesting when it was discovered that senescence has 
opposite effects in vitro and in vivo reprogramming. In vitro, the expression of the four Yamanaka 
factors (OCT3/4, SOX2, KLF4 and c- MYC, OSKM) activates senescence markers in targeting cells, 
such as SA-β-gal, p16INK4a, p21CIP1, and SAHF (Banito et al., 2009). This seemingly intrinsic barrier to 
reprogramming probably explains why the iPS cell generation efficiency is so low (≈0.02%) (Takahashi 
et al., 2007; Takahashi and Yamanaka, 2006). In fact, silencing of senescence- associated genes like 
p53, CIP1, and INK4a has been shown to increase iPS cell generation rate from mouse and human 
fibroblasts (Banito et al., 2009; Hong et al., 2009; Li et al., 2009). Strikingly, cellular senescence 
exerts a contrary effect on in vivo reprogramming. Such has been demonstrated in mice engineered 
to transiently express the four OSKM factors in an inducible fashion (i4F). i4F wild- type mice exhib-
ited co- expression of SA-β-gal and NANOG, a pluripotency marker (Mosteiro et al., 2016). Without 
INK4a/ARF, this co- expression was lost. Remarkably, in mouse models of lung and muscle damage 
in which senescence is induced at the lesion sites, the efficiency of reprogramming of i4F mice was 
increased (Chiche et al., 2017; Mosteiro et al., 2016). This efficiency was also enhanced in conditions 
that elicit senescence activation, including Palbociclib treatment, irradiation, and even aging. On the 
other hand, reprogramming was decreased after p16INK4a deletion or treatment with the senolytic drug 
ABT- 263 (Chiche et al., 2017; Mosteiro et al., 2016). This senescence- induced favourable environ-
ment for reprogramming was found to be mediated by secretion of the SASP factor IL- 6 that activates 
the JAK/STAT target PIM1 to promote cellular plasticity, which can be reverted by treatment with IL- 6 
antibodies (Chiche et al., 2017; Mosteiro et al., 2016). In another study, Ras- mediated OIS in the skin 
and liver was shown to induce the expression of stemness markers, such as CD34, Lgr6, and Nestin, in 
senescent keratinocytes (Ritschka et al., 2017). This was also demonstrated to be SASP- dependent, 
as it was abolished with nuclear factor kappa B (NF-κB) inhibition. However, the expression of stem-
ness markers was overcome by senescence features upon a longer (6 days) exposure to the OIS- driven 
SASP, which was proposed as a cell- intrinsic anti- tumourigenic response to counteract stemness. It is 
interesting to speculate that there is a risk that a short exposure to an oncogenic trigger can initiate a 
premature senescent response entailing a stemness profile with aberrant plasticity and high tumour- 
initiating capability. In any case, the relationship between senescence and reprogramming seems to 
be defined by the time of exposure to the SASP.
Targeting cellular senescence
The role of senescence in diverse pathological settings has elevated SCs to a hot target in a wide 
range of therapeutic approaches for injured or aged tissues (Paez- Ribes et al., 2019). Despite the 
proposition that removing SCs might extend lifespan, it becomes imperative to consider the potential 
drawbacks of removing SCs from certain tissues. In fact, a recent study has proven that senescent 
liver sinusoid endothelial cells have important structural and functional roles in the aging organism 
and cannot be replaced after removal (Grosse et al., 2020). Consequently, their acute elimination 
promoted liver and perivascular tissue fibrosis, as well as health deterioration. Nonetheless, in aging- 
related scenarios, targeting senescence has become considered targeting aging itself. Thus, the last 
few years have witnessed a boom in the development of senescence- targeted strategic tools with 
translational impact. Given the lack of a specific biomarker that could be used for specific targeting, 
current senescence- directed therapeutic approaches rely on three main strategies: (1) interference 
with important senescence pathways (e.g., pro- survival); (2) manipulation of the SASP; and (3) immune 
system activation (Paez- Ribes et al., 2019).
The work of Zhu et al., 2015, established the senolytics as a class of drugs that induce apoptosis 
in SCs by interfering with pathways that are crucial for the maintenance of the senescence pheno-
type. Transcriptomic analysis revealed the upregulation of pro- survival genes in SCs, namely those 
involving the anti- apoptotic PI3K/AKT pathway and BCL- 2 family proteins, as compared to normal 
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cells (Zhu et al., 2015), and identified drugs that can counteract the pro- survival genes and cause 
apoptosis. Senolytic approaches are currently the leading strategy to promote SC elimination in vivo 
(Paez- Ribes et al., 2019). Senolytic agents such as Dasatinib, Quercetin, and Navitoclax (also known 
as ABT- 263) are being tested in several clinical trials for the treatment of specific types of senescence/
age- associated disorders and cancer (Paez- Ribes et al., 2019). However, concerns with specificity 
and unwanted side effects may prove limiting factors for therapeutic development, hindering their 
translation into clinical interventions.
A specific modulation of the detrimental effects of the SASP without compromising the cell cycle 
arrest can be therapeutically advantageous. Of course, this requires a deep characterization of the 
SASP nature in each particular setting. In view of this, a number of molecules and antibodies aiming 
at interfering with transcriptional activators of the SASP (such as NF-κB, p38MAPK, and C/EBPβ) or 
neutralizing specific factors have already been developed (Paez- Ribes et al., 2019). Such compounds 
are called senostatics. Similarly to senolytics, there are essential aspects to consider when designing 
senostatics. First, all SASP transcriptional regulators also have non- senescence- associated functions 
and, thus, their targeting might generate undesirable side effects (Kang, 2019). Second, the SASP 
is very heterogeneous and the beneficial vs. the detrimental role of certain SASP factors seem to 
be context- or at least time- dependent. Therefore, a generalized inhibition of the SASP may prove 
disadvantageous.
The third strategy to target SCs consists on sensitizing immune cells to promote their clearance, 
a concept that may acquire particular relevance considering that the accumulation of SCs in aged 
tissues is thought to partially result from the development of escape mechanisms from immunosur-
veillance or a generally declining immune system (immunosenescence) (Furman et al., 2019). In vitro 
studies have reported evidence for NK and CD4+ T cell sensitization towards certain types of SCs 
upon administration of anti- DPP4 (a surface peptidase) and anti- Vimentin (membrane- bound protein) 
antibodies, respectively (Frescas et al., 2017; Kim et al., 2017). Recently, a ground- breaking study 
reported the senolytic potential of chimeric antigen receptor (CAR) T cells that target urokinase- type 
plasminogen activator receptor (uPAR), a cell- surface protein that was found to be broadly expressed 
during senescence (Figure 1; Amor et al., 2020). uPAR- specific CAR T cells were shown to efficiently 
eliminate SCs in different in vitro and in vivo contexts, unveiling a promising therapeutic strategy for 
senescence- associated pathologies.
A major advantage of adopting an immune sensitization strategy towards the use of senolytics and 
senostatics, which may systemically target pathways or factors that are not exclusive of senescence, is 
the efficiency in redirecting immune cells to target SCs with high specificity. Specificity is particularly 
relevant since we know that SCs can upregulate different markers depending on the context in which 
the senescence programme is triggered. For example, a recent study has established an association 
between the upregulation of CD9 (a membrane protein known to regulate cell adhesion and migra-
tion) in endothelial cells and atherosclerotic plaque formation (Cho et  al., 2020). CD9 regulated 
cellular senescence through a phosphatidylinositide 3 kinase- AKT- mTOR- p53 signalling pathway and 
its expression increased in arterial tissues with age, contributing to the pathogenesis of atheroscle-
rosis. In this context, specifically targeting CD9 may represent an ideal strategy for prevention and 
treatment of vascular aging.
From a therapeutic point of view, there is an urgent need of reliable tools for detection and 
targeting of different types of SCs in vivo. Nowadays, the development of novel fluorescent probes 
and the recent advances in nanotechnology are providing promising tools (e.g., theranostics) with 
serious translational potential for diagnosis and targeted treatment of senescence- associated disor-
ders (Paez- Ribes et al., 2019). However, these technologies need further exploration before clinical 
implementation.
Recently, it has been proposed that cellular senescence, contrarily to what was long thought, can 
be reverted. In 2018, Kornicka and colleagues demonstrated that a combination of 5‐Azacytydine and 
Resveratrol reversed the senescent phenotype of adipose stem cells through modulation of mitochon-
drial dynamics and autophagy (Kornicka et al., 2019). Upon this combinatorial treatment, adipose 
stem cells exhibited increased proliferation rate, decreased SA-β-gal activity, and lower reactive 
oxygen species (ROS) accumulation. Similar results were found in replicative senescent retinal pigment 
epithelial (RPE) cells co- cultured with embryonic stem cells (Wang et al., 2020). In this case, senescent 
RPE cells displayed increased proliferative capacity re- entering the S and G2/M cycle phases, along 
 Review article Cell Biology
Paramos- de- Carvalho et al. eLife 2021;10:e72449. DOI: https:// doi. org/ 10. 7554/ eLife. 72449  13 of 21
with the downregulation of several senescence biomarkers, such as SA-β-gal, p53, p21CIP1, p16INK4a. 
Though the mechanisms by which the senescent state can be reverted are still unclear, it has been 
shown that 3- phosphoinositide- dependent protein kinase 1 (PDK1) inhibition suppresses NF-κB and 
mTOR signalling and abolishes senescence hallmarks in senescent human dermal fibroblasts, restoring 
their quiescent state (An et al., 2020). The development of ‘senoreverters’ is thus rising as a prom-
ising alternative strategy to target SCs.
Hanging questions and considerations
While much progress has been achieved in understanding the biological roles of senescence, its 
apparently chaotic nature may yet reveal deeper complexities. How can we reconcile such a hetero-
geneous and puzzling phenomenon? Are there common fingerprints across different settings? In time, 
single- cell transcriptional analysis combined with machine learning tools will yield invaluable informa-
tion on context- specific senescent signatures and patterns.
Cellular senescence seems, fundamentally, a response to stress. It is becoming increasingly evident 
that SCs can be found in virtually any tissue. And, even though considerable knowledge was acquired 
on the possible different triggers of the senescence programme, it is still unclear how SCs are induced 
in vivo. Once this programme starts, how extensively does it modify the cellular phenotype in time? 
In other words, is a senescent fibroblast still a fibroblast? The same question will apply to every cell 
type. Importantly, the senescence programme entails deep epigenetic alterations which permit a 
tight regulation of transcriptional activities that is essential to its timely execution. This network was 
found to be orchestrated by activator protein 1 (AP- 1), who ‘imprints’ the senescence enhancer land-
scape that drives the transcriptional programme of SCs and determines their fate (Martínez- Zamudio 
et al., 2020). Upon a stress, what factors determine whether a cell undergoes senescence and not 
apoptosis? It has been suggested that the balance between senescence and apoptosis upon geno-
toxic stress is regulated by high mobility group box‐1 (HMGB1) proteins (Lee et al., 2019). In addi-
tion, a crosstalk between the telomere shortening/p53 and AKT/FoxO signalling pathways has been 
proposed to regulate an apoptosis- to- senescence switch during aging (El Maï et al., 2020).
It came as a surprise that senescence has a role to play in organismal life since very early on and may 
have originally arisen as a developmental mechanism. In fact, organs of regenerating animals, such as 
the zebrafish, often display senescence features during their developmental stages (Da Silva-Álvarez 
et al., 2020), suggesting a link between regeneration and the recapitulation of developmental senes-
cence. However, in non- regenerating scenarios, SCs exhibit disparate behaviours that lack a tight 
regulation like the one seen during embryogenesis.
The recent findings on the role of SCs in tissue injury and regenerative responses are quite exciting. 
Though their functions remain mostly undeciphered, SCs have been shown to facilitate fibrotic reso-
lution and also suggested to modulate cell plasticity during injury responses. These beneficial roles 
are primarily attributed to the SASP and are considered therapeutically relevant for pro- regenerative 
interventions. However, it is particularly pertinent to consider that many SASP factors are also known 
tissue damage signals secreted by non- SCs. Without a transcriptional analysis at the single- cell level, 
it will be hard to distinguish between them.
After all, are SCs good Samaritans or camouflaged villains? In this perspective, the reconciling 
factor seems to be ‘time’. The notion that the functions of SCs are orchestrated by temporally regu-
lated mechanisms is probably the most coherent senescence concept so far. While the beneficial roles 
of senescence all share a transient profile, the deleterious functions of SCs are associated to their 
lingering persistence, namely the chronic exposure to their SASP (Figure 2; Rhinn et al., 2019).
Targeting SCs is, for all the aforementioned reasons, currently a trending topic, so much so that 
several biotechnology companies are investing in the development of SC- targeted therapies with 
translational relevance. Yet, the lack of a specific senescence biomarker remains a limiting factor for effi-
cient translation. Moreover, there are important concerns regarding the clinical application of existing 
approaches. First, when is the right time to target senescence? Senescent profiles are highly dynamic 
and heterogeneous. Therefore, the timeframe of each senescence response should be accurately 
assessed in each particular setting in order to define an optimal therapeutic time- window. Second, 
how does the evolving senescence programme affect the feasibility of a senotherapy? It is known that 
each senolytic, senostatic, or immunosensitization approach targets a specific hallmark of senescence. 
In the case of the first two, it is usually an upregulated signalling pathway which is key to sustaining the 
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senescent phenotype and/or cell viability, while in the case of the latter can be any expressed marker 
deemed specific for a given SC type. However, it has become clear that the expression level of these 
hallmarks can significantly vary along the maturation of the senescence programme/response. These 
variations can thus determine the efficacy and success of distinct senotherapies in each particular point 
in time. Only a full time- wise phenotypic characterization can guarantee the optimal adequacy and 
effectiveness of a designed senotherapy. Third, SCs play important physiological roles in some specific 
contexts (e.g., wound healing) and, therefore, their general targeting must be carefully evaluated. This 
may be further complicated by the existence of different SC populations within the same context, as 
was recently demonstrated in the mouse liver where two distinct populations of p16INK4a+ and p21CIP1+ 
SCs have been shown to respectively promote and impair the regenerative capacity of the organ 
(Ritschka et al., 2020). Therefore, the selectivity of existing senolytics/senostatics must be improved 
and their delivery must be planned according to space and time. Nanoparticles represent a prom-
ising tool to specifically target pathological SCs in certain tissues, while diminishing drug- associated 
toxicity side effects, but this technology still needs further characterization and development. Ideally, 
targeting the SASP should aim at suppressing its deleterious effects while keeping or harnessing its 
beneficial roles. Yet, this will only be possible after an in- depth functional characterization of each 
SASP component in each different context. Another concern is that, given the multifaceted nature of 
SCs and the differences between humans and mice, existing pre- clinical studies might not reflect the 
complex microenvironment of diseased tissues from human aging- related disorders. Therefore, when 
possible, SC characterization and senotherapy validation should be performed in human samples ex 
vivo obtained from different contexts. In the future, this will likely be fundamental to generate person-
alized anti- senescent strategies.
A serious question to consider is whether, in the end, we really want to eliminate cells that were 
once a fundamental and integral part of our organismal homeostasis. This may be critical in tissues 
without the ability to regenerate or repopulate lost cells, such as the central nervous system. In certain 
scenarios, a revolutionary strategy would reside in being able to efficiently revert SCs to their original 
state. On this matter, the development of ‘senoreverters’ may emerge as a valuable targeting strategy 
for cellular senescence. However, we have seen that in certain contexts, like in cancer, the reversion 
of a pre- senescent state may result in highly aggressive growth behaviours. Thus, the possible reper-
cussions of using tools to revert the senescent state should be prudently examined. While such tools 
are yet to be refined, the pros and cons of targeting SCs should always be cautiously weighed in the 
balance. Beyond the how, finding the right when may prove to be the key for the success of a seno-
therapy. It is becoming increasingly clear that, in senescence, time is of the essence.
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